ArticleScientific reports2025
The role of GALAD score in the surveillance of hepatocellular carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AI-guided additive scoring model for differential diagnosis of primary liver cancer.JHEP reports : innovation in hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis of hepatocellular carcinoma (HCC) is essential in improving survival, creating a need for new markers in the early diagnosis and surveillance of HCC. This study aims to investigate the prediction of the GALAD score, which consists of gender, age, AFP, AFP-L3, and DCP, in the diagnosis of HCC in cirrhotic patients with normal AFP levels. GALAD scores were determined in 100 patients with cirrhosis and normal AFP in a tertiary center. The role of the GALAD score in the surveillance of HCC was investigated prospectively. 100 cirrhotic patients (59 male, mean age 60.4 ± 13.6 years) participated. GALAD score was higher in cases with HCC (GALAD = -0.66 in cases with HCC, and - 3.10 in cases without HCC, p < 0.001). The cut-off value of the GALAD score in the diagnosis of HCC was found to be -1.93 according to ROC analysis (AUC of 0.798, 95% CI: 70.5-89.1, sensitivity = 71%, specificity = 71%). In regression analysis, the risk of developing HCC was 3.4 times higher in patients with a GALAD score ≥ -1.93. The GALAD score is an important marker for the surveillance of HCC in cirrhotic patients with normal AFP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.